Skip to main content

Advertisement

Table 2 Patients and baseline characteristics

From: Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?

Characteristic
Age (yr), n (%)
 Median 47.5
 Range 28–61
Sex, male/female, n (%) 8 (44.4)/10 (55.6)
Primary lesion
 Pancreas 14 (77.8)
 Rectum 1 (5.6)
 Unknown origin 3 (16.7)
Site of target lesions, n (%)
 Pancreas (primary tumor) 11 (25.0)
 Liver 25 (56.8)
 Mesenteric lymph node 1 (2.3)
 Retroperitoneal lymph node 3 (6.8)
 Pelvic cavity 4 (9.1)
Pathological classification, n (%)
 Grade 1 2 (11.1)
 Grade 2 14 (77.8)
 Grade 3 2 (11.1)
Tumor functionality, n (%)
 Nonfunctioning 16 (88.9)
 Functioning 2 (11.1)
Previous treatments, n (%)
 None 11 (61.1)
 Surgery 4 (22.2)
Octreotide 1 (5.6)
 Transarterial chemoembolization 1 (5.6)
 Transarterial chemoembolization & Octreotide 1 (5.6)
Duration of sunitinib (months)
 Median 6.8
 Range 1.0–22.7
Time between initiation and first evaluation (months)
 Median 2.3
 Range 1.4–3.1
Duration of follow-up (months)
 Median 17.3
 Range 4.3–47.9